Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.56 |
| ▸ | NQO2 | P16083 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9113341 | 1.00 | ESR1 (1.00) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL3988719 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9622832 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL3988713 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL8393141 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL8393139 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL5692913 | 0.89 | ESR1 (0.80) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL5692915 | 0.89 | ESR1 (0.80) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9258161 | 0.84 | ESR1 (0.72) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9258167 | 0.84 | ESR1 (0.72) | ESR1ESR2PTGS1PTGS2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118995687-A | Fe (Fe)3O4@Al3+Preparation of material immobilized laccase and application of material immobilized laccase in degradation of ethylstilbestrol | 扬州大学 | 2024-11-22 | — | — | CN | claimed |
| CN-116539873-A | Diethylstilbestrol detection method based on photothermal probe and lateral chromatography test paper | 山东师范大学 | 2023-08-04 | — | — | CN | claimed |
| CN-116496407-A | Double-function fusion protein and preparation method and application thereof | 赋生康(上海)生物科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116439198-A | High-density breeding method for factory sheep raising | 安徽省天长市周氏羊业有限公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021072473-A1 | ANTIMICROBIALS AS FEED PRESERVATIVES | IRP Health Pty Ltd (AU) | 2021-04-22 | — | — | WO | claimed |
| WO-2018195202-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-10-25 | — | — | WO | claimed |
| US-20130219528-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | claimed |
| EP-2600855-A2 | COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2013-06-12 | — | — | EP | claimed |
| WO-2012018948-A2 | NOVEL TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| EP-2066679-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AEterna Zentaris GmbH (DE) | 2009-06-10 | — | — | EP | claimed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | claimed |
| WO-2003068229-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| CN-115368356-B | Bicyclic heterocyclic compounds and therapeutic uses thereof | 阿斯特克斯治疗有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-118995687-A | Fe (Fe)3O4@Al3+Preparation of material immobilized laccase and application of material immobilized laccase in degradation of ethylstilbestrol | 扬州大学 | 2024-11-22 | — | — | CN | disclosed |
| US-5382693-A | Curing agents for epoxy resins | THE DOW CHEMICAL COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| WO-1994026690-A1 | BIS(AMINOPHENOXY)-ALPHA-SUBSTITUTED STILBENES, CURABLE MIXTURES WITH EPOXY RESINS AND CURED PRODUCTS | THE DOW CHEMICAL COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5300594-A | Bis(aminophenoxy)-alpha-substituted stilbenes, curable mixtures with epoxy resins and cured products | THE DOW CHEMICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130219528-A1 | NOVEL TREATMENT OF PROSTATE CARCINOMA | KLK3, AR, PLK1 | ESR1 671/4885ESR2 486/4885PTGS1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.